SLU-PP-332 half-life is short in rodent studies—roughly one to two hours—but no human pharmacokinetic data exist. Learn what that means for dosing research.
SLU-PP-332 half-life is reported to be short — roughly one to two hours in rodent pharmacokinetic studies — and no human half-life has been published, because SLU-PP-332 has never gone through human clinical trials. That short window is the main reason researchers dose the compound repeatedly rather than once a day, and it explains why "how long does it last?" is one of the most common questions about it.
What Is SLU-PP-332?
For anyone starting with what is slu-pp-332: it is an experimental estrogen-related receptor (ERR) agonist developed by researchers at Saint Louis University and studied in mice as a possible exercise mimetic.
In rodent research, SLU-PP-332 has been associated with increased fatty acid oxidation, greater mitochondrial content in muscle tissue, and improved endurance on treadmill tests. Those are animal findings, not proven human outcomes.
The compound is a research chemical. It is not FDA-approved, not a prescription medicine, and not a legal dietary supplement ingredient in the United States.
What the Research Says About the SLU-PP-332 Half-Life
Half-life is the time it takes for half of a dose to clear from the bloodstream. Publicly available data for SLU-PP-332 come almost entirely from rodent studies, where plasma levels fall quickly after a single dose.
- Estimated plasma half-life: about 1–2 hours in mice, depending on the assay and route used.
- Human half-life: unknown. No human pharmacokinetic study has been published.
- Dosing in animal studies: typically daily or twice-daily administration to maintain measurable exposure.
- Confidence level: low to moderate, because small animal groups and different formulations make exact figures hard to pin down.
Searches for slu-pp-332 half life usually surface vendor pages and forum posts, and those numbers are almost always borrowed from the same small set of mouse studies. Anyone quoting a precise human half-life — whether two hours, four hours, or eight — is extrapolating from animal data.
Why a Short Half-Life Changes Dosing
With a one- to two-hour half-life, a single dose leaves very little active compound in circulation after a few hours. That is why slu-pp-332 dosage in published mouse work is repeated rather than spaced widely apart.
Half-life also matters for expectations. Two hours of plasma exposure does not automatically mean two hours of biological effect, because ERR signaling alters gene transcription and downstream effects can outlast the drug itself.
Oral vs. injected
The phrase "slu pp 332 oral half life" shows up often because route of administration changes the picture. Oral bioavailability for SLU-PP-332 appears limited in animal models, largely due to first-pass metabolism in the liver.
Route primarily changes absorption, peak concentration, and total exposure rather than the elimination half-life itself. In practice, that means lower and more variable blood levels from oral use, which is one reason slu-pp-332 oral dosage per day discussions are speculation rather than data.
SLU-PP-332 vs. MOTS-c: How Half-Lives Compare
People researching metabolic and performance compounds often compare slu-pp-332 vs mots-c, and clearance speed is one of the sharpest differences between them. MOTS-c is a peptide, and peptides generally leave circulation faster than small molecules.
| Compound | Reported half-life | Data source and notes |
|---|---|---|
| SLU-PP-332 | Roughly 1–2 hours | Rodent pharmacokinetics; no human data published |
| MOTS-c | Minutes to about 1 hour | Peptide hormone; short circulating life in published reports |
| GW501516 (cardarine) | About 16–24 hours | Human trial data; linked to cancer in rodents and not approved |
These figures come from different species, assays, and routes of administration, so they are not directly comparable. A half-life table tells you about clearance speed, not about safety or effectiveness, and these compounds are not interchangeable.
What Can Shift a Half-Life Estimate
A single "official" half-life for SLU-PP-332 does not exist. Several variables move the number up or down:
- Species: mouse liver enzymes do not process compounds the same way human enzymes do.
- Route: injection versus oral dosing changes absorption and peak blood levels.
- Formulation: DMSO, PEG, and lipid-based carriers affect how quickly a compound is absorbed.
- Dose size: high doses can saturate clearance pathways and artificially extend apparent half-life.
- Assay sensitivity: different labs and detection methods can produce different results from the same compound.
Body composition, liver enzyme activity, age, and interactions with other compounds can also influence clearance. None of these factors have been studied for SLU-PP-332 in people.
Safety, Human Data, and What to Do With This Information
There are no published slu-pp-332 human trials, no established safe dose, and no long-term safety data. Reported adverse effects on forums and vendor sites are anecdotal, unverified, and cannot substitute for clinical evidence.
Because ERR pathways overlap with estrogen-related biology, questions about hormonal effects remain open in the scientific literature. Related compounds in the metabolic research space have shown serious problems in animals — cardarine, for example, was linked to cancer in rodent studies.
SLU-PP-332 is sold as a research chemical, which means purity is not verified, human use is not approved, and no dosing protocol has been validated. Anyone weighing it should speak with a licensed healthcare professional first.
Key Takeaways
- SLU-PP-332 half-life is short — roughly one to two hours in rodent studies.
- No human pharmacokinetic data exist, so any human half-life figure is an estimate.
- A short half-life means frequent dosing in animal research, not convenient once-daily dosing.
- Oral use produces lower, more variable exposure than injection in animal models.
- SLU-PP-332 is not FDA-approved for human use in the United States.
Frequently Asked Questions
What is the half-life of SLU-PP-332?
Published rodent studies suggest a plasma half-life of roughly one to two hours. No human pharmacokinetic study has been published, so the human half-life remains unknown. Any specific human figure circulating online is an extrapolation from animal data.
Does SLU-PP-332 have a different half-life when taken orally?
Route of administration mainly changes absorption and peak blood levels, not the elimination half-life, which is driven largely by liver metabolism. Oral bioavailability for SLU-PP-332 appears low in animal models, so oral use produces lower and more variable exposure. There is no validated human oral dosing or oral half-life data.
Is SLU-PP-332 approved for human use?
No. SLU-PP-332 is not FDA-approved and has not completed human clinical trials. It is sold as a research chemical, so purity and safety are not regulated and it is not intended for human consumption. Anyone considering it should consult a licensed healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.